Journal of Gastroenterology

, Volume 49, Issue 6, pp 1040–1046 | Cite as

Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer

  • Kotaro Hirashima
  • Masayuki Watanabe
  • Hironobu Shigaki
  • Yu Imamura
  • Satoshi Ida
  • Masaaki Iwatsuki
  • Takatsugu Ishimoto
  • Shiro Iwagami
  • Yoshifumi Baba
  • Hideo Baba
Original Article—Alimentary Tract



The Glasgow prognostic score (GPS) is a preoperatively determined inflammation-based score. Reports suggest a significant correlation between the GPS and prognosis in several cancer types. We aimed to clarify the prognostic significance of the modified GPS (mGPS) in patients undergoing gastrectomy for gastric cancer.


Two hundred and ninety-four patients with gastric cancer, 195 aged < 75 years (group NE) and 99 aged > 75 years (group E), who underwent gastrectomy from March 2005 to March 2011 were enrolled. Patients with an elevated C-reactive protein level (> 0.5 mg/dL) and hypoalbuminemia (< 3.8 g/dL) were assigned a mGPS of 2, those with either 1 abnormality were assigned a mGPS of 1, and those with neither abnormality were assigned a mGPS of 0. Cox proportional hazard models and Kaplan–Meier analysis were used to evaluate the usefulness of mGPS as a prognostic indicator.


In the NE group, the prognosis of the 3 groups stratified by mGPS did not differ significantly. In multivariate Cox regression analysis, the type of gastrectomy, peritoneal metastasis, and stage were independently associated with poor prognosis. However, group E patients with a mGPS of 2 had significantly poorer prognosis than those with a mGPS of 0 or 1. In this age group, stage and mGPS were independently associated with poor prognosis.


In patients aged > 75 years undergoing potentially curative gastrectomy, the preoperative mGPS was an independent predictor of survival. Therefore, mGPS can be a useful prognostic indicator in elderly patients with gastric cancer.


mGPS Gastric cancer Prognostic marker 



The contents of this manuscript are the sole responsibility of the authors. Those who funded the study had no role in the study design, data collection, and analysis; decision to publish; or preparation of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

535_2013_855_MOESM1_ESM.docx (37 kb)
Supplementary tables (DOCX 38 kb)


  1. 1.
    Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5:5–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Tatebe S, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg. 2006;76:458–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur J Surg Oncol. 2010;36:709–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Watanabe M, Iwatsuki M, Iwagami S, Ishimoto T, Baba Y, Baba H. Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg. 2012;36:1632–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe M, Miyata H, Gotoh M, Baba H, Kimura W, Tomita N, et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg. 2013; in press.Google Scholar
  6. 6.
    Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637–41.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 2011;11:489.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2012;106:279–83.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994;69:911–3.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7:331–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2009;100:1236–9.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008;144:729–35.PubMedCrossRefGoogle Scholar
  16. 16.
    Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201:186–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Dutta S, Al-Mrabt NM, Fullarton GM, Horgan PG, McMillan DC. A comparison of POSSUM and GPS models in the prediction of post-operative outcome in patients undergoing oesophago-gastric cancer resection. Ann Surg Oncol. 2011;18:2808–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.Google Scholar
  20. 20.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.Google Scholar
  21. 21.
    Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.PubMedCrossRefGoogle Scholar
  22. 22.
    La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19:2917–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma. 1998;31:351–7.PubMedGoogle Scholar
  25. 25.
    Crumley AB, Stuart RC, McKernan M, McDonald AC, McMillan DC. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2008;23:e325–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92:1834–6.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91:205–7.Google Scholar
  29. 29.
    Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS, et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg. 2004;8:1041–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34:2393–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008;101:978–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus. 2005;18:146–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 2000;89:255–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer. 1996;77:2445–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Kotaro Hirashima
    • 1
  • Masayuki Watanabe
    • 1
  • Hironobu Shigaki
    • 1
  • Yu Imamura
    • 1
  • Satoshi Ida
    • 1
  • Masaaki Iwatsuki
    • 1
  • Takatsugu Ishimoto
    • 1
  • Shiro Iwagami
    • 1
  • Yoshifumi Baba
    • 1
  • Hideo Baba
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations